1 / 27

The Essentials

Canadian Diabetes Association 2013 Clinical Practice Guidelines. The Essentials. Learning Objectives. By the end of this session, participants will be able to: Understand the major changes within the 2013 CDA clinical practice guidelines Understand the rationale behind these changes

jaime-avery
Télécharger la présentation

The Essentials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Canadian Diabetes Association 2013 Clinical Practice Guidelines The Essentials

  2. Learning Objectives By the end of this session, participants will be able to: • Understand the major changes within the 2013 CDA clinical practice guidelines • Understand the rationale behind these changes • Apply the recommendations in clinical practice 

  3. Faculty for slide deck development • Jonathan Dawrant, BSc, MSc, MD, FRCPC • Zoe Lysy, MDCM, FRCPC • GeethaMukerji, MD, FACP, FRCPC • Dina Reiss, MD, FACP, FRCPC • Steven Sovran, BSc, MD, MA, FRCPC • Alice Y.Y. Cheng, MD, FRCPC • Peter J. Lin, MD, CCFP • Catherine Yu, MD, FRCPC, MHSc

  4. www.guidelines.diabetes.ca

  5. guidelines.diabetes.ca

  6. Diagnosis of Diabetes 2013 2hPG = 2-hour plasma glucose; FPG = fasting plasma glucose; OGTT = oral glucose tolerance test; PG = plasma glucose

  7. Diagnosis of Prediabetes* 2013 * Prediabetes = IFG, IGT or A1C 6.0 - 6.4%  high risk of developing T2DM

  8. 2013 Individualizing A1C Targets Consider 7.1-8.5% if: which must be balanced against the risk of hypoglycemia

  9. AT DIAGNOSIS OF TYPE 2 DIABETES L I F E S T Y L E Start lifestyle intervention (nutrition therapy and physical activity) +/- Metformin A1C <8.5% A1C 8.5% Symptomatic hyperglycemia with metabolic decompensation If not at glycemic target (2-3 mos) Start metformin immediately Consider initial combination with another antihyperglycemic agent Initiate insulin +/- metformin Start / Increase metformin If not at glycemic targets Add an agent best suited to the individual: Patient Characteristics Degree of hyperglycemia Risk of hypoglycemia Overweight or obesity Comorbidities (renal, cardiac, hepatic) Preferences & access to treatment Other Agent Characteristics BG lowering efficacy and durability Risk of inducing hypoglycemia Effect on weight Contraindications & side-effects Cost and coverage Other 2013 See next page…

  10. From prior page… L I F E S T Y L E If not at glycemic target • Add another agent from a different class • Add/Intensify insulin regimen 2013 Make timely adjustments to attain target A1C within 3-6 months

  11. Vascular Protection Checklist 2013 • A• A1C – optimal glycemic control (usually ≤7%) • B•BP – optimal blood pressure control (<130/80) • C•Cholesterol – LDL ≤2.0 mmol/L if decided to treat • D•Drugs to protect the heart (regardless of baseline BP or LDL) A – ACEi or ARB │S – Statin │A – ASA if indicated • E• Exercise / Eating healthily – regular physical activity, achieve and maintain healthy body weight • S•Smoking cessation

  12. Who Should Receive Statins? (regardless of baseline LDL-C) 2013 • ≥40 yrs old or • Macrovascular disease or • Microvascular disease or • DM >15 yrs duration and age >30 years or • Warrants therapy based on the 2012 Canadian Cardiovascular Society lipid guidelines Among women with childbearing potential,statins should only be used in the presence of proper preconception counseling & reliable contraception. Stop statins prior to conception.

  13. What if baseline LDL-C ≤2.0 mmol/L? • Within CARDS and HPS, the subgroups that started with lower baseline LDL-C still benefited to the same degree as the whole population • If the patient qualifies for statin therapy based on the algorithm, use the statin regardless of the baseline LDL-C and then target an LDL reduction of ≥50% HPS Lancet 2002;360:7-22 Colhoun HM, et al. Lancet 2004;364:685.

  14. 2013 Who Should Receive ACEi or ARB Therapy?(regardless of baseline blood pressure) • ≥55 years of age or • Macrovascular disease or • Microvascular disease At doses that have shown vascular protection [perindopril 8 mg daily (EUROPA), ramipril 10 mg daily (HOPE), telmisartan80 mg daily (ONTARGET)] Among women with childbearing potential,ACEi or ARB should only be used in the presence of proper preconception counseling & reliable contraception. Stop ACEi or ARB either prior to conception or immediately upon detection of pregnancy EUROPA Investigators, Lancet 2003;362(9386):782-788. HOPE study investigators. Lancet. 2000;355:253-59. ONTARGET study investigators. NEJM. 2008:358:1547-59

  15. Recommendation 2013 ASA should not be routinely used for the primary prevention of cardiovascular disease in people with diabetes [Grade B, Level 2] ASA may be used in the presence of additional cardiovascular risk factors [Grade D, Consensus]

  16. 2013 Chronic Kidney Disease (CKD) Checklist • SCREEN regularly with random urine albumin creatinine ratio (ACR) and serum creatinine for estimated glomerular filtration rate (eGFR) • DIAGNOSE with repeat confirmed ACR ≥ 2.0 mg/mmol and/or eGFR < 60 mL/min • DELAY onset and/or progression with glycemic and blood pressure control and ACE inhibitor or angiotensin receptor blocker (ARB) • PREVENT complications with “sick day management” counselling and referral when appropriate

  17. Counsel all Patients About Sick Day Medication List 2013

  18. 2013 Diabetes in the Elderly Checklist • ASSESS for level of functional dependency (frailty) • INDIVIDUALIZE glycemic targets based on the above (A1C ≤ 8.5% for frail elderly) but if otherwise healthy, use the same targets as younger people • AVOID hypoglycemia in cognitive impairment • SELECT antihyperglycemic therapy carefully • caution with sulfonylureas or thiazolidinediones • Basal analogues instead of NPH or human 30/70 insulin • Premixed insulins instead of mixing insulins separately • GIVE regular diets instead of “diabetic diets” or nutritional formulas in nursing homes

  19. Need a preconception checklist for women with pre-existing diabetes 2013 • 1. Attain a preconception A1C of ≤ 7.0% (if safe) • 2. Assess for and manage any complications • 3. Switch to insulin if on oral agents • 4. Folic Acid 5 mg/d: 3 mo pre-conception to 12 weeks post-conception • 5. Discontinue potential embryopathic meds: • Ace-inhibitors/ARB (prior to or upon detection of pregnancy) • Statin therapy

  20. Tools to help us keep track of our patients

  21. Tools to help us keep track of our patients

  22. Back Page: “Cheat Sheet” of Targets and Goals

  23. Back Page: “Cheat Sheet” of Targets and Goals

  24. New resources

  25. Download the App Today!

  26. “Neither evidence nor clinical judgment alone is sufficient. Evidence without judgment can be applied by a technician. Judgment without evidence can be applied by a friend. But the integration of evidence and judgment is what the healthcare provider does in order to dispense the best clinical care.” (Hertzel Gerstein, 2012)

More Related